| |
New Study Showed Vytorin Significantly More Effective than Crestor at Lower LDL
|
| |
| |
http://www.therapeuticsdaily.com
PharmaLive News Archive - 17-Jun-2006
The primary endpoint of the study was LDL cholesterol reduction from baseline averaged across all doses. In a post-hoc subgroup analysis of 715 high risk patients included in the study, the results revealed that VYTORIN, as a result of greater LDL cholesterol reduction, helped significantly more high-risk patients achieve an LDL cholesterol of less than 70 mg/dL and less than 100 mg/dL compared to patients taking Crestor (50 percent vs. 29 percent; p <0.001 and 90 percent vs. 82 percent, p<0.05 respectively) averaged across the doses studied.
Summary
- In addition, both VYTORIN and Crestor raised HDL "good" cholesterol by 8 percent, averaged across all doses studied.
- The primary endpoint of the study was LDL cholesterol reduction from baseline averaged across all doses.
- Key secondary endpoints included LDL cholesterol reductions from baseline at each dose comparison.
- With the results of this study, VYTORIN now has been shown in clinical studies to provide greater LDL cholesterol lowering efficacy versus Zocor (simvastatin), Lipitor (atorvastatin) and Crestor (rosuvastatin) at all study dose comparisons.
- In a post-hoc subgroup analysis of 715 high risk patients included in the study, the results revealed that VYTORIN, as a result of greater LDL cholesterol reduction, helped significantly more high-risk patients achieve an LDL cholesterol of less than 70 mg/dL and less than 100 mg/dL compared to patients taking Crestor (50 percent vs. 29 percent; p <0.001 and 90 percent vs. 82 percent, p<0.05 respectively) averaged across the doses studied.
- "In this study, VYTORIN was significantly more effective than Crestor in reducing LDL cholesterol and averaged across the doses in attaining an LDL cholesterol goal of less than 100 mg/dL and LDL cholesterol of less than 70 mg/dL in high-risk patients," said Michael Davidson, M.D., professor of medicine, director of Preventive Cardiology, Rush University Medical Center, Chicago.
- "These data provide further evidence that VYTORIN is an excellent option to help lower the LDL, or bad, cholesterol levels of patients with high cholesterol."
- The results were presented today at the International Symposium on Atherosclerosis (ISA 2006) meeting in Rome.
|
|
| |
| |
|
|
|
